Nexaura is a biotechnology R&D company, founded in 2026 and grounded in a decade of building and running operational functions inside drug development companies, from discovery science through clinical operations to translational R&D and supply-chain infrastructure. Its product, Nexaura Intelligence, turns that experience into an AI engine that flags supply and shortage risk, finds second sources, and reads the market.
The best operational decisions are made quietly, early, and by people who have lived with the consequences. That is the standard Nexaura holds.
Nexaura is grounded in a decade of hands-on practice across the full drug development value chain: from early discovery and immuno-oncology research, through CAR-T clinical operations, to the end-to-end build-out of translational R&D laboratories and their procurement and supply chains.
That experience, running these functions rather than advising on them from a distance, shapes how every engagement is structured.
What it kept surfacing, across biotech, industry, hospitals and the public sector, was the same gap: teams making high-stakes decisions about manufacturing partners, second sources and suppliers with incomplete information, scattered across dozens of sources and reaching them too late to act.
Nexaura exists to close that gap.
Early-stage medicinal chemistry and immuno-oncology research, a technical foundation in how molecules move from concept to clinic.
Clinical trial management across CAR-T cell-therapy programs, plus pharmacovigilance, through some of their most operationally complex phases.
End-to-end build-out of a translational research laboratory: procurement, supplier qualification, and supply-chain management.
That decade of operational practice, now built into a product: an AI engine for supply-risk signals, second sources and market intelligence.
Nexaura combines deep scientific training with a decade of hands-on operational practice across the drug development value chain. That expertise is what powers Nexaura Intelligence.